This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
A guide bar, typically an elongated bar with a round end of wear-resistant alloy steel typically 40 to 90 cm (15.5 to 35.5 in) in length, is used. An edge slot guides the cutting chain. Specialized, loop-style bars, called bow bars, were also used at one time for bucking logs and clearing brush, although they are now rarely encountered due to increased hazards of operation. The lower part of the chain runs in the gauge. Here, the lubrication oil is pulled by the chain to the nose. This is basically the thickness of the drive links.
=== Bacteria === Three species of bacteria, Carnobacterium pleistocenium, Chryseobacterium greenlandensis, and Herminiimonas glaciei, have reportedly been revived after surviving for thousands of years frozen in ice. Certain bacteria, notably Pseudomonas syringae, produce specialized proteins that serve as potent ice nucleators, which they use to force ice formation on the surface of various fruits and plants at about −2 °C. The freezing causes injuries in the epithelia and makes the nutrients in the underlying plant tissues available to the bacteria. Listeria grows slowly in temperatures as low as -1.5 °C and persists for some time in frozen foods.
=== EC 2.1.3: Carboxy- and Carbamoyltransferases === EC 2.1.3.1: methylmalonyl-CoA carboxytransferase EC 2.1.3.2: aspartate carbamoyltransferase EC 2.1.3.3: ornithine carbamoyltransferase EC 2.1.3.4: deleted EC 2.1.3.5: oxamate carbamoyltransferase EC 2.1.3.6: putrescine carbamoyltransferase EC 2.1.3.7: 3-hydroxymethylcephem carbamoyltransferase EC 2.1.3.8: lysine carbamoyltransferase EC 2.1.3.9: N-acetylornithine carbamoyltransferase EC 2.1.3.10: malonyl-S-ACP:biotin-protein carboxyltransferase EC 2.1.3.11: N-succinylornithine carbamoyltransferase EC 2.1.3.13: The enzyme has been replaced by EC 6.1.2.2 EC 2.1.3.14: The enzyme has been replaced by EC 6.1.2.2 EC 2.1.3.15: acetyl-CoA carboxytransferase
The Life Sciences Institute (LSI) is a collaborative, multidisciplinary research institution located on the campus of the University of Michigan in Ann Arbor. It encompasses 27 faculty-led teams from 13 schools and departments throughout U-M. Of the university's $823 million in research expenditures, more than half is allocated for research in the life sciences, and the LSI is a cornerstone of this effort.
Sources: en.wikipedia.org
=== SRA === SRA (Stationary-phase-induced Ribosome-Associated protein) is not well understood as of 2018. It is a small protein of 45 amino acids and is tightly associated with the 30S ribosomal subunit. It increases from an average of 0.1 molecules per ribosome to 0.4 per ribosome during the transition to stationary phase and remains so for several days.
Barry Windsor-Smith, who had come to prominence illustrating Marvel's Conan the Barbarian series, collaborated with Claremont for the "Wounded Wolf" story that was published as Uncanny X-Men #205 (May 1986), focusing entirely on Wolverine. The story introduced a new adversary for Wolverine, Lady Deathstrike. The "Mutant Massacre" story arc of 1986 brought Sabretooth into conflict with the X-Men and particularly Wolverine. Byrne had previously designed Sabretooth as an enemy of the martial artist superhero Iron Fist in Iron Fist #14 (August 1977), written by Claremont. Sabretooth's face was based on a preliminary and unused drawing Byrne had proposed for Wolverine; he became Wolverine's archenemy. Marvel launched an ongoing Wolverine title written by Claremont with art by John Buscema in November 1988. In the late 1980s, Wolverine featured in self-contained crossover stories with two other characters: Spider-Man, in Spider-Man versus Wolverine (1987), by Christopher Priest and M.D. Bright, and Nick Fury, in Wolverine/Nick Fury: The Scorpio Connection (1989), written by Archie Goodwin with art by Howard Chaykin.
The signs and symptoms of ankylosing spondylitis often appear gradually, with peak onset between 20 and 30 years of age. Initial symptoms are usually a chronic dull pain in the lower back or gluteal region combined with stiffness of the lower back. Individuals often experience pain and stiffness that awakens them in the early morning hours. As the disease progresses, loss of spinal mobility and chest expansion, with a limitation of anterior flexion, lateral flexion, and extension of the lumbar spine are seen. Systemic features are common with weight loss, fever, or fatigue often present. Pain is often severe at rest but may improve with physical activity. Inflammation and pain may recur to varying degrees regardless of rest and movement. AS can occur in any part of the spine or the entire spine, often with pain localized to either buttock or the back of the thigh from the sacroiliac joint. Arthritis in the hips and shoulders may also occur. When the condition presents before the age of 18, AS is more likely to cause pain and swelling of large lower limb joints, such as the knees. In prepubescent cases, pain and swelling may also manifest in the ankles and feet, where heel pain and enthesopathy commonly develop. Less common occurrences include ectasia of the sacral nerve root sheaths. About 30% of people with AS will also experience anterior uveitis, causing eye pain, redness, and blurred vision. This is thought to be due to the association that both AS and uveitis have with the presence of the HLA-B27 antigen.
Sources: en.wikipedia.org
In the East, the Soviet Union had installed dictatorial governments, controlling East Germany, and the rest of Eastern Europe. Although Stalin died in 1953 and the new general secretary Nikita Khrushchev had denounced him in 1956, Soviet tanks crushed a democratic Hungarian Revolution of 1956, and repressed every other attempt of its people to win democracy and human rights.
=== Tuberous sclerosis complex === Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in the genes TSC1 and TSC2. TSC1 produces the protein hamartin. TSC2 produces the protein tuberin. This disorder presents with many benign hamartomatous tumors including angiofibromas, renal angiomyolipomas, and pulmonary lymphangiomyomatosis. Tuberin and hamartin inhibit the mTOR protein in normal cellular physiology. Inactivation of the TSC tumor suppressors causes an increase in mTOR activity. This leads to the activation of genes and the production of proteins that increase cell growth.
== Further reading == Glickman, N; Mitchell, HH (Jul 10, 1948). "The total specific dynamic action of high-protein and high-carbohydrate diets on human subjects" (PDF). The Journal of Nutrition. 36 (1): 41–57. doi:10.1093/jn/36.1.41. PMID 18868796.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.